Fenofibrate and Pharmacogenetic Impact in Dyslipidemia

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to learn whether genetics plays a role in predicting response to a commonly used and FDA (Food and Drug Administration) approved medication for lowering triglycerides and cholesterol. The hypothesis: The pharmacogenetics of genes which affect drug metabolism (how the body handles the drug) and drug targets (how the drug acts on the body) influences how a person responds to the lipid lowering medication-fenofibrate.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Minnesota; University of Minnesota - Clinical and Translational Science Institute
• Collaborator: Laval University
• Treatments: Fenofibrate

Criteria

Inclusion Criteria:

• 18-75 year old

• Be willing to participate in the study and attend the scheduled clinic exams

• Consent to taking lipid lowering therapy for 4 weeks and if necessary discontinue lipid lowering agents for a period of 8 weeks

Exclusion Criteria:

• <18 years of age

• History of liver, kidney, pancreas, pancreatitis, gall bladder disease or malabsorption (Crohn's disease etc.)

• Use of insulin or currently taking warfarin

• Pregnant women or women of childbearing potential not using an acceptable form of contraception

• History of an allergy or hypersensitivity to fenofibrate

• Investigational drug use within 30 days of the study

• A disease that, in the opinion, of the PI, would put the subject at risk during the study